Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Acute myeloid leukemia

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

Leukemia volume 35, pages 295–298 (2021)Cite this article

Subjects

“The more I learn, the more I realize how much I don’t know”—Albert Einstein

“The more I learn, the more I realize how much I don’t know”—Albert Einstein

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bernard J, Boiron M, Jacquillat C, Weil M, Najean Y. Un nouvel agent actif dans le traitement des leucémies aiguës: la cytosine arabinoside. Presse Med. 1966;74:799–802.

    CAS  PubMed  Google Scholar 

  2. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507–23.

    Article  CAS  Google Scholar 

  3. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009;10:1657–74.

    Article  CAS  Google Scholar 

  4. Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics. 2015;16:877–90.

    Article  CAS  Google Scholar 

  5. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485–8.

    CAS  PubMed  Google Scholar 

  6. Coltman CA Jr, Bodey GP, Hewlett JS, Haut A, Bickers J, Balcerzak SP, et al. Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin. Arch Intern Med. 1978;138:1342–8.

    Article  Google Scholar 

  7. Ho DH, Frei E 3rd. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharm Ther. 1971;12:944–54.

    Article  CAS  Google Scholar 

  8. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 1979;44:1189–93.

    Article  CAS  Google Scholar 

  9. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987;47:3005–11.

    CAS  PubMed  Google Scholar 

  10. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121:26–28.

    Article  Google Scholar 

  11. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.

    Article  CAS  Google Scholar 

  12. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–9.

    CAS  PubMed  Google Scholar 

  13. Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greinix HT, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130:946–8.

    Article  CAS  Google Scholar 

  14. Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017;7:e564.

    Article  CAS  Google Scholar 

  15. Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, et al. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020;4:3840–9.

    Article  CAS  Google Scholar 

  16. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841–51.

    Article  CAS  Google Scholar 

  17. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710–7.

    Article  CAS  Google Scholar 

  18. Garcia-Manero G, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, et al. SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML) [abstract]. Blood. 2016;128:901.

    Article  Google Scholar 

  19. Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, et al. Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia. Clin Cancer Res. 2020;26:3154–61.

    Article  CAS  Google Scholar 

  20. Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Ann Oncol. 2018;29:973–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Roland B. Walter, Frederick R. Appelbaum & Elihu H. Estey

  2. Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA

    Roland B. Walter & Elihu H. Estey

  3. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

    Roland B. Walter

  4. Department of Epidemiology, University of Washington, Seattle, WA, USA

    Roland B. Walter

  5. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA

    Frederick R. Appelbaum

Authors
  1. Roland B. Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick R. Appelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elihu H. Estey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roland B. Walter.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walter, R.B., Appelbaum, F.R. & Estey, E.H. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. Leukemia 35, 295–298 (2021). https://doi.org/10.1038/s41375-020-01110-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-01110-3

This article is cited by

Search

Advanced search

Quick links